Brief: Oncolytics Biotech says Reolysin doubles survival in breast cancer patients
April 5 (Reuters) - Oncolytics Biotech Inc ONC.TO
* Oncolytics Biotech inc says Reolysin more than doubles
overall survival in patients with mutated p53 metastatic breast
cancer
* Oncolytics Biotech -patients with mutated p53 metastatic
breast cancer saw a statistically significant improvement in
median overall survival
Source text for Eikon: ID:nPn3qW6BVa
Further company coverage: ONC.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer